Latent says pharmacy AI now live in 60 health systems, adds autonomous agents

Latent, an enterprise pharmacy intelligence company, said it is now live in 60 leading U.S. health systems serving about 70 million patients, naming new customers including Cleveland Clinic, AdventHealth, Cincinnati Children’s, Keck Medicine of USC, UNC Health, UnityPoint Health, and WVU Medicine. The same announcement unveiled autonomous clinical agents that work inside health-system pharmacy workflows — with clinical oversight — to speed access to high-demand drugs such as GLP-1s and complex specialty therapies.

HEALTH desk priority — same-day primary showing pharmacy AI agents scaling across major U.S. health systems as specialty-drug access bottlenecks grow.

New customers named on the same page: Cleveland Clinic, AdventHealth, Cincinnati Children’s, Keck Medicine of USC, UNC Health, UnityPoint Health, and WVU Medicine. File those seven names as Latent’s. This desk did not interview the systems or independently certify go-live dates.

Same announcement, still company: a suite of autonomous clinical agents designed to accelerate patient access to high-demand drugs including GLP-1s and a new wave of highly complex specialty therapies across immunology, rheumatology, and cardiology. GLP-1s are a popular diabetes and weight-loss drug class. Specialty drugs are high-cost, complex medicines that often need extra pharmacy-team work. File that agent product as Latent’s. This desk did not watch an agent run and is not saying the software replaces pharmacists.

How the agents work, as the company tells it: they process unstructured data in the patient chart, claims, payer policies, and drug labels, reason across that information, and act inside each health system’s workflows. The company says the agents operate in controlled health-system workflows with oversight from clinical pharmacy teams. File that chart-to-workflow picture and the oversight frame as Latent’s. This desk did not audit a prior-authorization file.

Forward look, company-attributed: Latent says it is on pace to process more than 5.8 million patient medication journeys in the next 12 months, spanning prior authorizations, compliance readiness reviews, and pharmacy work queues. A prior authorization is insurer paperwork required before a plan covers a drug. File the 5.8 million line as Latent’s forward-looking claim. This desk did not count journeys.

Example claim, still company: after Medicare launched the GLP-1 Bridge Program on July 1, 2026, Latent says about 4 million Medicare members became eligible overnight, and the company deployed agents in 10 days to evaluate eligibility and gather the information needed to submit prior authorizations. File the July 1 date, the 4 million line, and the 10-day deploy as Latent’s. This desk did not review CMS program files or watch that deploy.

Market size, Latent citing Global Market Insights — not independently verified here: the specialty drug market was $226 billion in 2024 and is expected to grow to over $2.3 trillion by 2034; specialty drugs now make up 50% of U.S. pharmacy drug spending. File those figures as Latent citing GMI, not as a desk fact-check. This desk did not rerun the market model.

Named voices on the company page: Sri Somasundaram, co-founder of Latent; Robert Granko, Pharm.D., MBA, System Vice President, Pharmacy Business Operations at UNC Health; Aman Mahajan, Associate Senior Vice President, USC Health Innovation; and Charles Barkey, Vice President, Clinical Applications at WVU Medicine. File the names and titles as Latent’s. Their quotes are color only and stay in Sources.

Plain English for the rest of the card: prior authorization = insurer paperwork before covering a drug. specialty drugs = high-cost complex medicines that often need pharmacy teams. GLP-1s = a popular diabetes and weight-loss drug class. autonomous clinical agents here = software that can draft and gather access steps inside hospital rules with pharmacist oversight.

PRIMARY here: Latent’s 15 Sep 2026 company newsroom — Tier A PRIMARY company source, the original record. The company site is product-home context, not a second originating newsroom. The 60 health systems / about-70-million-patients live footprint, the Cleveland Clinic / AdventHealth / Cincinnati Children’s / Keck Medicine of USC / UNC Health / UnityPoint Health / WVU Medicine names, the autonomous clinical-agent suite for GLP-1s and specialty therapies, the chart / claims / payer-policy / label ingest plus pharmacy-team oversight, the more-than-5.8-million-journeys forward look, the Medicare GLP-1 Bridge / 4 million / 10-day example, the $226 billion / $2.3 trillion / 50% specialty-spend figures Latent cites to Global Market Insights, and the Somasundaram / Granko / Mahajan / Barkey names are company-attributed. Customer names, journey counts, deploy timing, and market-size figures stay company- or GMI-via-Latent-attributed — not independently verified here. NOT claimed: FDA device clearance, a funding round, independently verified patient or system counts, that the agents replace clinicians, clinical efficacy, that this desk sat in a pharmacy or reviewed a prior-authorization file, a stock tip, or investment advice. Distinct from the already-filed aitiologic-6-4m-seed, openai-foundation-public-data-health, unc-openai-foundation-40m-cancer-vaccines, insilico-longevity-vaccines, openevidence-penn-medicine, microstructure-imaging-micsi-pet-fda, sonus-medtronic-maternal-ultrasound-ai, powerful-medical-queen-of-hearts-fda-de-novo, kairon-health-5m, evvy-40m-series-b, hello-patient-acquires-converse, medallion-acquires-andros, and knowtex-frontier-ai-lab.